drugset / Trial / NCT04625985

Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

NCT04625985 ↗

Phase 2 Completed 20 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.

Timeline

Start
2020-07-14
Primary completion
2021-03-08
Completion
2021-03-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 620 mg Oral

Indications